鹽野製藥(SGIOY.US)正在尋求日本批準新冠疫苗S-268019
格隆匯11月24日丨鹽野製藥(SGIOY.US)週四表示,已在日本申請批準其實驗性COVID-19疫苗。兩天前,日本監管機構緊急批準鹽野製藥新冠口服治療藥物,這是日本國內製藥企業首次獲得批準的新冠口服治療藥物。
鹽野木在一份聲明中說,重組蛋白疫苗S-268019的申請是基於日本五項臨牀試驗的結果。
該公司試圖將這種疫苗作爲對抗新冠的初級疫苗和增強劑進行營銷。
鹽野木上個月上調了全年銷售預期,因預期該公司將獲得監管部門的批準。該公司已經簽署了向日本政府出售約100萬劑疫苗的協議,目前正在等待批準。該公司還獲得了美國政府的資金,用於全球試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.